BioCentury
ARTICLE | Company News

Chugai Pharmaceutical Co. Ltd, Eli Lilly sales and marketing update

November 12, 2012 8:00 AM UTC

Eli Lilly and Chugai terminated a deal to co-commercialize Evista raloxifene, effective Dec. 31. Following the termination, Lilly will be responsible for marketing the product in Japan, where it is a...